BSE filing, NSE: ONESOURCE. Summary written from the filing by ALFA Finder's alert engine.
OneSource Specialty Pharma Ltd: key numbers
- Share price
- ₹1,577.60
- Market cap
- ₹18,091 Cr
- Revenue (annual)
- ₹1,422 Cr
- Net profit (annual)
- ₹-73.80 Cr
- P/E (TTM)
- -11160.2×Sector 46.1×
- Promoter holding
- 30.47%-0.01% QoQ
- FII holding
- 19.45%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from OneSource Specialty Pharma Ltd
All →OneSource Specialty Pharma Earnings Call Transcript: Key Takeaways
Onesource Specialty Pharma delivered its third consecutive growth quarter, driven by new sterile cartridge capacity.
OneSource Specialty Pharma Results Update
OneSource announced Q2FY27 results with revenue up 37% YoY and EBITDA up 53% YoY. An investor presentation was filed alongside the press release.
OneSource Specialty Pharma Employee Stock Options
OneSource Specialty Pharma allotted 360 equity shares under its ESOP 2021 scheme to an eligible employee. Paid-up share capital increased to 11,46,74,151 shares of ₹1 each.
OneSource Specialty Pharma Management Change
Dr. Claudio Albrecht's designation changed from Independent Director to Non-Executive Non-Independent Director, effective 27 Oct 2026. The change is subject to shareholder approval at the upcoming meeting.
OneSource Specialty Pharma Q2 FY27 Results: Net Profit ₹57.5 Cr, Up 447.6% YoY
OneSource Specialty Pharma Ltd reported revenue from operations of ₹516.2 Cr (+37.4% YoY) and net profit of ₹57.5 Cr (+447.6% YoY) for Q2 FY27.
- Key figure
- Net profit ₹57.5 Cr · +447.6% YoY
OneSource Specialty Pharma Board Meeting Date
OneSource Specialty Pharma Limited scheduled a board meeting for October 27, 2026, to consider the company's unaudited financial results for the quarter ended September 2026.
Other management change announcements
All →iStreet Network Management Change
iStreet Network Ltd announced the resignation of Non-Executive Non-Independent Director Mr. Yash Maheshwari effective 13 October 2026. No financial impact is indicated.
Transgene Biotek Management Change
Transgene Biotek's statutory auditors Eswara Rao & Co. resigned effective 28 October 2026 citing pre-occupation. The company will appoint new auditors per applicable regulations.
Mobavenue AI Tech Management Change
Mobavenue AI Tech appointed Vikram Sheth as Chief of Corporate Development and Investor Relations. He will lead fundraising, acquisitions and investor relations.
Hexaware Technologies Management Change
Hexaware appointed Arjun Shah and Gregory Zeluck as Non-Executive Directors from 28 October 2026. Directors Neeraj Bharadwaj and Julius Genachowski resigned, and Girish Pai's resignation is effective 13 November 2026.
GMR Airports Management Change
GMR Airports appointed Sanjeev Gupta as Executive Director (Deputy CEO) effective 29 October 2026. Non-Executive Director Alexis Riols resigned effective 28 October 2026.
Raymond Realty Management Change
Raymond Realty said joint statutory auditor Chaturvedi & Shah LLP resigned on 28 October 2026 after a dispute over audit fee revision. Walker Chandiok & Co LLP continues as the other statutory auditor.